文献速递血液透析通路

比较一期与二期贵要静脉转位动静脉瘘的患者特异性因素与结局

Comparison of patient-specific factors and outcomes for one- and two-stage basilic vein transposition fistulas.
PubMed 文献 · J Vasc Surg · 2018-05-24

该回顾性研究比较了2008至2013年间本院49例一期与169例二期贵要静脉转位动静脉瘘,发现两组在成熟率、一期通畅率、一期辅助通畅率、二期通畅率及并发症率上相似,且与静脉直径无关;糖尿病与两种术式的主要失败均相关;二期组多数主要失败和导管相关感染发生于两期间隔期,作者认为可考虑一期技术以减少导管感染风险并缩短成熟时间。

要点

  • 一期与二期贵要静脉转位动静脉瘘的成熟率、各期通畅率及并发症率相似
  • 糖尿病与两种术式的主要失败均相关(OR 1.60,95%CI 0.95-2.55,P=0.07)
  • 二期组主要失败和导管相关感染多发生于两期间隔期,作者认为可考虑一期技术

核心结论

  • 一期与二期贵要静脉转位动静脉瘘在成熟率、一期通畅率、一期辅助通畅率、二期通畅率及并发症率上相似,与静脉直径无关;糖尿病与两种术式的主要失败均相关;二期组多数主要失败和导管相关感染发生于两期间隔期,作者认为可考虑一期技术以减少导管感染风险并缩短成熟时间。

研究设计与样本

  • 回顾性研究,纳入2008年至2013年间在本院接受一期或二期贵要静脉转位动静脉瘘的全部患者,共49例一期和169例二期。

主要发现

  • 一期与二期患者的平均年龄分别为58岁和61岁,两组贵要静脉近端、中段、远端平均直径无差异。
  • 主要失败(成熟失败)在一期组为26.5%,二期组为24.3%(P=0.78)。
  • 2年一期通畅率一期组51% vs 二期组52%(P=0.68);一期辅助通畅率一期组66% vs 二期组85%(P=0.05);二期通畅率一期组64% vs 二期组78%(P=0.26)。
  • 多因素logistic回归显示糖尿病患者主要失败风险有升高趋势(OR 1.60,95%CI 0.95-2.55,P=0.07)。
  • 二期组两期间隔期中位时间为105.00天(四分位距77.00-174.50天),期间发生主要失败19/41(46%)和导管相关感染12/20(60%)。

临床怎么用

  • 作者认为,鉴于二期贵要静脉转位动静脉瘘的主要失败和导管相关感染高比例发生于两期间隔期,可考虑一期技术以尽量减少导管感染风险并缩短成熟时间。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The decision to perform a one- or two-stage basilic vein transposition (BVT) arteriovenous fistula often depends on factors such as the vessel's diameter, the patient's disposition, and the surgeon's preference. This study's aim was to analyze patency by BVT staging technique and to identify patient-specific characteristics associated with outcomes. METHODS: A retrospective review of all patients who underwent one- or two-stage BVT at our institution between 2008 and 2013 was performed. Comparisons of age, sex, race, and associated comorbidities were made. Clinical course was followed for 2 years after fistula construction, comparing maturation rate, thrombosis, stenosis, steal, and catheter infections. Continuous variables were expressed as means or medians and compared across stage and maturation groups by t-test; differences between categorical variables were assessed using Fisher exact test. A Kaplan-Meier survival analysis was performed to calculate patency rates and compared by log-rank test. RESULTS: There were 49 one-stage and 169 two-stage BVTs examined. The mean age of the patients at time of construction was 58 years and 61 years for one-stage and two-stage patients, respectively. There was no difference in mean proximal, mid, or distal basilic vein diameters between the groups. Fistula maturation was similar between stage groups, with primary failure affecting 26.5% of one-stage and 24.3% of two-stage BVTs (P = .78). Across one- and two-stage BVTs, 2-year primary patency rates were 51% and 52%, respectively (P = .68); primary assisted patency, 66% and 85% (P = .05); and secondary patency, 64% and 78% (P = .26). Multivariate logistic regression showed a trend toward diabetics at higher risk for primary failure (odds ratio, 1.60; 95% confidence interval, 0.95-2.55; P = .07). For two-stage BVT, the median interstage period between operations lasted 105.00 (interquartile range, 77.00-174.50) days and was associated with a large proportion of the overall primary failures (19/41 [46%]) and catheter-related infections (12/20 [60%]). CONCLUSIONS: This study demonstrates similar maturation, primary patency, primary assisted patency, secondary patency, and complication rates in a large series of BVTs constructed using a one- or two-stage transposition technique regardless of vein diameter. Diabetes was associated with primary failure by either technique. High proportions of overall primary failures and catheter-related infections observed in two-stage BVT occurred during the interstage, suggesting that a one-stage technique should be considered over a two-stage approach to minimize the risk of catheter infection and to decrease time to maturity.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Shevitz AJ, Kim AH, Morrow KL, et al. Comparison of patient-specific factors and outcomes for one- and two-stage basilic vein transposition fistulas. J Vasc Surg. 2018. PMID: 29803681. doi:10.1016/j.jvs.2018.02.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。